

Pharmacy and Therapeutics Committee

Meeting Minutes

Thursday, October 18, 2018
7:00 a.m. to 8:45 a.m.
Cannon Health Building
Room 125

Committee Members Present:

McKay Robinson, PharmD
Clinton Sheffield, MD
Elizabeth Young, PharmD

Bryan Larson, PharmD
Cole Sloan, PharmD

Committee Members Excused:

Susan Siegfried, MD
Clayton Grace, RPh

Jake Jones, MD

Dept. of Health/Div. of Health Care Financing Staff Present:

Robyn Seely, PharmD

Merelynn Berrett, RN

University of Utah Drug Regimen Review Center Staff Presenter:

Elena Martinez

Other Individuals Present:

Jennifer Lauper, Bristol-Myers Squibb
Charissa Anné, J&J
Mohit Bhakta, Select Health
Cody Ball, Select Health
Roy Lindfield, Sunovion

Gary Okano, Bristol-Myers Squibb
Danny McNatty, Janssen
Valerie Gonzales, U of U
Rob Booth, Allergan
Patrick Moty, Horizon Pharma

Meeting conducted by: Committee Chair

1. **Welcome & Housekeeping:** McKay Robinson opened the meeting and announced a quorum.
2. **Review and Approval of September and corrected June Minutes:** Beth Young made a motion to approve the minutes from September. Clinton Sheffield seconded the motion. All in favor, motion passed.
3. **Drug Utilization Review (DUR) Board update:** The DUR board met last week to discuss Hemlibra. Next month, the DUR board will discuss macrolides.
4. **Non-Vitamin K Anticoagulants for Venous Thromboembolism and Nonvalvular Atrial Fibrillation:** (apixaban, betrixaban, dabigatran, dalteparin, desirudin, edoxaban, enoxaparin, fondaparinux, rivaroxaban). Elena Martinez presented a review of Non-Vitamin K Anticoagulants for Venous Thromboembolism and Nonvalvular Atrial Fibrillation. She presented peer reviewed research regarding the safety and efficacy of each agent, clinical trials,

disease-state treatment guidelines and Utah Medicaid utilization data.

5. Public Comment:

- a. Danny McNatty from Janssen presented information pertaining to Xarelto.
- b. Gary Okano from Bristol-Myers Squibb presented information pertaining to Eliquis.

6. Other State Report: Bryan Larson reported PDL listings for agents in this class in other States' Medicaid programs.

7. Committee Discussion:

- a. Cole Sloan asked Elizabeth Young about her knowledge and experience regarding therapeutic drug monitoring with these agents. Dr. Young briefly characterized the limitations of such monitoring and why it not become routine practice to implement.
- b. Elizabeth Young asked Elena Martinez about weight based limitations with these agents. Ms. Martinez confirmed that there are weight based limitations. Bryan Larson asked about the limitations. Dr. Young responded that patients with a weight greater than 120 kg should not use these agents due to the increased risk of venous thromboembolism.
- c. Elizabeth Young made a motion that all non-vitamin K anticoagulants are equally safe and efficacious for inclusion on the PDL. Clinton Sheffield seconded the motion. Unanimous approval, motion passed.
- d. McKay Robinson made a motion that at least two oral non-vitamin K anticoagulants be preferred on the PDL. Clinton Sheffield seconded. Unanimous approval, motion passed.
- e. Clinton Sheffield made a motion that at least one injectable low molecular weight heparin be preferred on the PDL. Cole Sloan seconded. Unanimous approval, motion passed.

8. Public Meeting Adjourned: McKay Robinson motioned to close the meeting. Bryan Larson seconded the motion. Unanimous approval, motion passed.

9. Next meeting is scheduled for November 15, 2018 Migraine Prophylaxis.

Audio recording of all P&T meetings are available online at:

<https://medicaid.utah.gov/pharmacy/pt-committee?p=Committee%20Meeting%20Audio%20Recordings>